The Denosumab Drug Holiday Fallacy: Osteomorphs, Overshoot, and Rebound

*Denosumab* is a widely used *monoclonal antibody* that inhibits bone resorption, but its effects wear off rapidly upon discontinuation, triggering a dangerous *rebound phenomenon* characterized by a surge in osteoclast activity. This exaggerated bone turnover often leads to *multiple vertebral fractures* and *rebound hypercalcemia**, particularly in pediatric populations and patients receiving high oncologic doses or prolonged therapies. Because stopping this medication abruptly carries significant risks, medical management requires **careful biochemical monitoring* and *sequential antiresorptive therapy* such as bisphosphonates rather than taking unmonitored drug holidays. Healthcare providers must recognize this *PTH-independent complication* early to prevent severe outcomes like acute kidney injury and to properly differentiate it from malignant causes of high blood calcium. Ultimately, effective prevention hinges on *individualized bridging strategies* and maintaining vigilant post-treatment surveillance to safely counteract the skeletal calcium efflux and rapid bone density loss associated with denosumab cessation.